title: [A case report of interstitial pneumonia caused by granulocyte colony-stimulating factor].
abstract: Several clinical trials have demonstrated that granulocyte colony-stimulating factor (G-CSF) accelerates the recovery of neutropenia in chemotherapy-induced bone marrow suppression. In this report, we describe a 46-year-old female with glioblastoma multiforme who developed interstitial pneumonia due to administration of G-CSF during the phase of immunochemoradiotherapy-induced neutropenia. Thirty-three days after starting immunochemoradiotherapy (ACNU, VCR, IFN -beta, radiation), she developed neutropenia (1,000/microliters). Administration of G-CSF at doses of 125-250 micrograms/day led to an increase of peripheral neutrophil counts. Eleven days later, the patient developed sudden severe respiratory failure and cyanosis with worsening of lung shadows. Blood gas levels on room air were PaO2 49.3mmHg, PaCO2 28.0mmHg, and pH 7.46. At this time, her neutrophil count had risen to 26,080/microliters. LDH and alpha - HBD had also increased to 1,439 IU/l and 1,117IU/l respectively. Chest radiograph and CT scan demonstrated interstitial pneumonia. After treatment with methyl prednisolone, her respiratory symptoms were gradually resolved. A number of side-effects have been reported with granulocyte-macrophage colony-stimulating factor (GM-CSF). These include fluid retention with pericardial and pleural effusion, fever, bone pain, fatigue, and rash. This report also suggests that G-CSF might be a cause of interstitial pneumonia during the phase of immunochemoradiotherapy-induced neutropenia.
authors.affiliation: Department of Neurosurgery, Sapporo Medical University School of Medicine.
authors.forename: Y
authors.initials: Y
authors.lastname: Ibayashi
authors.forename: H
authors.initials: H
authors.lastname: Ohyama
authors.forename: Y
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: K
authors.initials: K
authors.lastname: Sakatani
authors.forename: S
authors.initials: S
authors.lastname: Morimoto
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Shibata
authors.forename: S
authors.initials: S
authors.lastname: Kashiwabara
authors.forename: S
authors.initials: S
authors.lastname: Tanabe
authors.forename: K
authors.initials: K
authors.lastname: Hashi
mesh_terms: D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005909:Glioblastoma / Q000276:immunology / Q000628:therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D017563:Lung Diseases, Interstitial / Q000209:etiology*; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology / Q000628:therapy*
chemical_list: D016179:Granulocyte Colony-Stimulating Factor